Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative therapy for myelofibrosis. Despite improved outcomes, morbidity and mortality of HSCT remain high. Here we examine recent data on patient selection, timing, and outcomes of HSCT in myelofibrosis.
INTRODUCTION
Mr T. is a 52-year-old gentleman presenting with progressive weight loss, abdominal distention, pain, night sweats, and early satiety. On examination, he is cachectic with massive splenomegaly extending to the pelvic rim. Laboratory studies reveal a white blood cell count of 32.9 Â 10 3 /ml, left-shifted myeloid series with 8% circulating blasts, a hemoglobin of 13.0 g/dl, and platelets of 475 000/ml. Lactate dehydrogenase (LDH) is elevated at 1857 units/l. JAK2 p.V617F mutation is detected. Bone marrow biopsy reveals a hypercellular, markedly fibrotic marrow, with megakaryocytic hyperplasia and atypia, morphologically consistent with primary myelofibrosis. Karyotype is normal. Ruxolitinib is started with rapid improvement in constitutional and spleen-related symptoms. The risks and benefits of hematopoietic stem cell transplantation (HSCT) are discussed, and HSCT is recommended. A stem cell donor search is initiated.
Myelofibrosis is a chronic myeloproliferative neoplasm (MPN), characterized by cytopenias and constitutional symptoms, megakaryocytic hyperplasia, reactive marrow fibrosis, and extramedullary hematopoiesis [1] . Myelofibrosis can occur as a primary disorder, primary myelofibrosis (PMF), or as a secondary disorder following a diagnosis of polycythemia vera or essential thrombocythemia, post-polycythemia vera or post-essential thrombocythemia myelofibrosis [2] . A recent epidemiologic study in the United States estimated an annual Intermediate-2 and high-risk myelofibrosis patients have worse HSCT outcomes than patients with low-risk disease; the difference is largely accounted for by their increased TRM.
When adjusted for age, RIC-HSCT has shown better outcomes compared with myeloablative transplantation; additional studies are needed.
Current data provide greatest support for flu/bu-based conditioning for the majority of patients.
Emerging concepts include the use of ruxolitinib pretransplant, optimizing myeloablative regimens to decrease toxicity, and use of posttransplant JAK2mutant allele burden to guide prophylactic immunotherapy to prevent relapse. for PMF patients longitudinally over their disease course, are the Dynamic-IPSS (DIPSS), which places a higher emphasis on anemia [7] , as well as the DIPSS-Plus, which incorporates transfusion dependence, platelet count under 100 000/ml, and unfavorable karyotype [8] . Increased hepcidin (>3 standard deviations of normal) and ferritin levels (>500 mg/l) were found to predict inferior overall survival (OS) independent of the DIPSS-Plus category [9] . Additional high-risk features predictive of dismal prognosis were reported by several groups: blasts at least 10% in peripheral blood or bone marrow, platelet count less than 50 000/ml, and chromosome 17 abnormalities were each associated with a median survival of under 12 months [10] . A monosomal karyotype, presence of i17q and inv(3) abnormalities, or any two of peripheral blasts more than 9%, leukocyte count more than 40 Â 10 3 /ml, or other unfavorable karyotype predicted a 2-year mortality of 80% [11] .
Leukemic transformation of myelofibrosis is associated with poor outcomes [17] and remains the most feared complication of myelofibrosis. DIPSS intermediate-2 and high-risk groups have an increased risk of leukemic transformation, with a hazard ratio of 7.8 and 24.9 [18] , respectively. Additional prognostic models further refined the leukemic transformation risk stratification. Tefferi et al. [12] identified high-risk karyotype [monosomal karyotype or i17q/inv(3)], circulating blasts at least 2%, and a platelet count less than 50 000/ml as factors predictive of low, intermediate, or high 3-year leukemic transformation risk of 3, 10, and 34%, respectively. Bone marrow blasts more than 10% and high-risk karyotype (del 17p, -5, -7 or complex) were predictive of a 1-year leukemic transformation rate of 13% [13] . Barbui et al. [14] reported an alternative prognostic system for leukemic transformation, using high-sensitivity C-reactive protein at least 7 mg/l, age at least 65 years, and peripheral 
Clonal molecular changes of adverse prognostic significance in myelofibrosis [15]
1 Unfavorable karyotype: complex karyotype or single or two abnormaliƟes including +8,-7/7q-, i(17q),-5/5q-, 12p-, inv(3) or 11q23 rearrangement. 2 Very high risk karyotype: monosomal karyotype or inv(3)/i(17q). 3 Worst karyotype: del17p, -5, -7, and/or complex. blasts at least 1% to stratify patients into three risk groups with an 8-year leukemia-free survival of 88, 48, and 32%, respectively. Undoubtedly, these clinical variables have clonal molecular underpinnings. There is growing evidence that many mutations affect prognosis, some independent of the clinical risk category [15] . Vannucchi et al. [15] evaluated the prognostic significance of somatic mutations in ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL, and JAK2 in a European cohort of myelofibrosis patients; mutations in ASXL1, EZH2, SRSF2, and IDH1/2 were associated with poor outcomes.
Mutationally high-risk patients, defined as carrying at least one mutation in these four genes, had a worse OS and a higher risk of leukemic transformation than patients without these mutations, independent of their IPSS risk. In a validation cohort from Mayo Clinic, mutations in ASXL1, SRSF2, and EZH2 were associated with worse OS, and mutations in IDH1 and SRSF2 with leukemic transformation. In a multivariate analysis, mutations in ASXL1 had negative prognostic significance, independent of the IPSS and DIPSS-Plus category [15] . Mechanistically, ASXL1 loss-of-function mutations appear to promote myeloid transformation by dysregulation of Polycomb-mediated gene silencing [19] . Adverse prognostic significance of the EZH2, IDH, and SRSF2 mutations, independent of the risk category, was previously reported [20] [21] [22] .
In summary, emerging data on prognostic importance of somatic mutations and factors predictive of leukemic transformation add a new dimension to risk stratification for myelofibrosis. It has been generally accepted that myelofibrosis patients with a predicted OS of less than 5 years (corresponding to the IPSS and DIPSS intermediate-2 and high categories) should be considered for a HSCT [23] . In our practice, we also integrate age and symptom burden of disease in the risk-benefit assessment: that is, a 66-year-old with incidentally discovered, asymptomatic intermediate-2 disease and a hemoglobin of 12 g/dl is not someone for whom we recommend immediate transplantation, whereas a person in their 40s with transfusionrequiring anemia but only intermediate-1 disease may strongly want to consider HSCT. While the clinical prognostic scoring systems (IPSS, DIPSS, and DIPSS-Plus) remain the cornerstone of risk assessment, recognition of adverse significance of molecular markers (ASXL1, EZH2, SRSF2, and IDH1/2) and the increasing appreciation of clinical factors associated with very poor prognosis and leukemic transformation, may tip the balance in borderline cases. TRANSPLANTATION FOR  MYELOFIBROSIS: WHEN? 'SICK ENOUGH  TO NEED IT, BUT WELL ENOUGH TO  TOLERATE IT' Clinical heterogeneity and high transplant-related mortality (TRM) in myelofibrosis make the timing of HSCT particularly difficult. To date, there are no prospective studies evaluating the optimal timing of HSCT in myelofibrosis, nor are there decision analyses, such as for myelodysplastic syndrome [24] , that rigorously compare outcomes of HSCT to nontransplant therapies in patients with different disease risk. This is particularly problematic in light of the general gains in survival in myelofibrosis patients over the last decade, largely independent of HSCT outcomes [4, 25] , as well as owing to the significant improvements in quality of life and, perhaps, a modest survival advantage with ruxolitinib [26] . Thus, the question of whether and to what degree high-risk patients truly benefit from transplant is complicated and ultimately remains unanswered. The decision to transplant lower risk patients is similarly highly individualized.
HEMATOPOIETIC STEM CELL
Several studies have evaluated HSCT outcomes as predicted by the myelofibrosis prognostic scores and other potentially relevant variables. In a recent European study of 150 patients treated with reduced intensity conditioning (RIC), high-risk patients, defined by IPSS and DIPSS, had significantly worse OS than intermediate-2 patients. In contrast, there was no difference in OS between the low/intermediate-1 and intermediate-2 prognostic groups [27] . The Seattle group found, however, that among 170 patients transplanted with either myeloablative conditioning (MAC) or RIC-HSCT, high and intermediate-2 DIPSS risk patients had a significantly worse OS compared to the low DIPSS risk patients [28] . Notably, most of the difference was attributable to TRM, which was 3.41 times higher in the high-risk compared with the low-risk patients. While there was a correlation between the DIPSS risk and the HSCT comorbidity index (HCT-CI) [29] , the DIPSS category retained an association with HSCT outcomes even after adjusting for HCT-CI. Inferior OS after HSCT for intermediate-2 and high-risk patients compared with low-risk patients was confirmed in an independent study of 76 patients with myelofibrosis treated with MAC-HSCT [30] . In both studies, in a multivariate analysis, the increased mortality in the higher risk categories was not associated with higher relapse rates. Although several variables appeared to have independent prognostic significance in individual studies, overall there was no consistent relationship between HSCT outcomes and JAK2 V617F mutation status, prior splenectomy, history of transfusions, degree of marrow fibrosis, or the patient's age [27, 28, 30] . To date, there is no evidence that acquired molecular changes affect HSCT outcomes in myelofibrosis, although data are scant and this is an active area of investigation [31] .
Taken together, available data indicate that intermediate-2 and high-risk myelofibrosis patients have inferior outcomes, largely accounted for by their increased TRM [27, 28, 30] . We can speculate that this reflects the high catabolic state, cachexia, and increased cytokine levels in this patient population, which are not otherwise captured by current prognostic systems. Pretransplant use of ruxolitinib has, therefore, been proposed as a possible strategy to improve transplant outcomes [32, 33] by improving performance status, reversing the catabolic state, and reducing the spleen size, and is being investigated in an ongoing phase II study by the Myeloproliferative Disorder-Research Consortium.
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: WHAT ARE THE TRUE BENEFITS?
The vast majority of data on HSCT in myelofibrosis come from retrospective multicenter and registry analyses spanning three decades from the late 1970s through 2000s ( Fig. 4) [28, 30, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . The variety of conditioning regimens, inherent patient selection bias, and improvements in HSCT over time largely preclude meaningful comparisons across studies, and make it difficult to reliably identify transplant-specific or patient-specific factors that influence outcomes. Here we present a synthesis of historical results with a focus on the most recent findings; for a more comprehensive overview, we refer the reader to several recent in-depth reviews [33, 47, 48] . The early experience with HSCT for myelofibrosis relied on MAC, primarily total body irradiation (TBI)-based or using busulfan/cyclophosphamide (Bu/Cy), with targeted busulfan introduced in later years. Outcomes were poor, with the long-term OS of 30-60%, event-free survival (EFS) of 25-50%, and a sobering TRM of 30-40% (Fig. 4) . Recurrent factors associated with increased mortality were mismatched or unrelated donor, nontargeted busulfan dosing, older age (with a cut-off of 40-60 years among different studies [38] [39] [40] 45, 49] ), poor performance status, and high risk or transformed disease.
The introduction of RIC-HSCT, with a significantly lower 1-year TRM of 12-25%, and as low as 12-13% for fully matched sibling and unrelated donor transplants [49, 50] , both confirmed the concept that myelofibrosis is a reversible, immunoresponsive entity and expanded the option of transplantation to older patients. The long-term OS with RIC-HSCT ranges from a low of 31% in 24 patients treated with a predominantly fludarabine/ melphalan (flu/mel)-based conditioning [37] to a high of 67-68% with largely fludarabine/busulfan (flu/bu)-based regimens [42, 45] (Fig. 4) . The largest and the only published prospective multicenter study of RIC-HSCT in myelofibrosis, conducted by the European Group for Blood and Marrow Transplantation (EBMT), evaluated outcomes of 103 patients with PMF and postpolycythemia vera/ postessential thrombocythemia myelofibrosis treated with flu/bu conditioning in combination with antithymocyte globulin (ATG, Fresenius) [45] . The median patient age was 54 years. The 1-year TRM was 16%, with a cumulative incidence of relapse at 3 years of 22%. The 5-year OS and EFS were 67 and 51%, respectively. Age over 55 years and a mismatched graft correlated with inferior outcomes. An alternative RIC-HSCT regimen of flu/mel AE ATG with a peripheral blood stem cell (PBSC) graft is being evaluated in an ongoing prospective phase II study (MPD-RC 101). An interim analysis of 42 patients with a median age of 54 years revealed a low TRM of 13% in 23 matched related donor (MRD) transplants, but an unexpectedly high TRM of 47% in the 19 matched unrelated donor (MUD) transplants [50] .
Although there are no prospective trials comparing myeloablative and RIC-HSCT, there are multiple retrospective analyses comparing outcomes of MAC-HSCT and RIC-HSCT in myelofibrosis [35, 37, 39, 40, 42, 51, 52] . Despite being on average 10 years older, patients transplanted with RIC have similar outcomes to patients transplanted with MAC [35, 39, 40, 42, 51, 52] . When adjusted for age, RIC had superior outcomes in a recent analysis of 92 patients from Nordic countries, where RIC patients had an estimated 5-year OS 78% compared with 52% for MAC for patients under 53 years, and a 5-year OS of 44% compared with 38% for patients 53 years and older [39] . Within the RIC group, outcomes were significantly better for patients under 60 with an estimated 5-year OS of 75% as compared with 20% for older patients. The poor outcomes in the older population in this study were worse than the previously reported 45% 3-year OS and 40% EFS in 30 patients aged 60-78 years [43] .
Additional prospective studies are needed to generate more precise estimates of HSCT outcomes in myelofibrosis. Myelofibrosis patients are particularly susceptible to early hepatotoxicity after HSCT, including sinusoidal obstruction syndrome (SOS), which is associated with TRM [53] . In an effort to reduce toxicity of MAC, Rezvani et al. [46] prospectively evaluated the use of intravenous cyclophosphamide followed by targeted busulfan (Cy/ t Bu) in patients with hematologic malignancies, including 20 patients with myelofibrosis. The pharmacologic rationale was to reduce toxicity of cyclophosphamide by maximizing the stores of hepatic glutathione, necessary for cyclosphophomide detoxification and normally depleted by busulfan. Compared to historical controls treated with targeted busulfan followed by cyclophosphamide ( t Bu/Cy), patients treated with Cy/ t Bu had a significantly lower incidence of hepatotoxicity and SOS, and lower 100-day TRM (2 vs. 13%) [46] . Although this small study found no significant difference in 2-year TRM or OS, this may be a promising approach for intensifying conditioning while limiting toxicity, and merits further study.
CAN WE MONITOR AND INTERVENE ON PERSISTENT OR MINIMAL RESIDUAL DISEASE?
Emerging areas of investigation include the use of JAK2 p.V617F allele burden in patients with JAK2mutated myelofibrosis to identify patients at a higher risk of relapse [54, 55] . Lange et al. [54] reported that JAK2 p.V617F allele burden of at least 1% on day 28 after MAC-HSCT or RIC-HSCT was predictive of relapse in a cohort of 30 patients with JAK2-mutated MPN; future studies are needed to validate the predictive value of early post-HSCT JAK2 mutation burden in myelofibrosis patients with a more defined conditioning regimen. Donor lymphocyte infusion (DLI) has shown promise as a salvage therapy in the setting of relapse, minimal residual disease, and graft rejection [45, 56, 57] and proves definitively the immunoresponsiveness of myelofibrosis. We hope that additional biologic insights will inform novel studies of cellular therapy for myelofibrosis.
CONCLUSION
Despite improvements in outcomes in HSCT for myelofibrosis, TRM remains high, underscoring the importance of judicious patient selection and appropriate HSCT timing. Our recommended approach is to consider HSCT in patients with intermediate-2 and high-risk disease as defined by DIPSS or DIPSS-Plus criteria, and to incorporate prognostic information from the known adverse molecular markers (ASXL1, EZH2, SRSF2 and IDH1/2) and leukemic transformation risk factors, as well as age and symptom burden as guidance in borderline cases. In all transplant-eligible patients, we advocate identifying available donor options early, even if no immediate recommendation for HSCT is made, so that patients can move efficiently toward transplant should their disease evolve. With respect to the timing of HSCT, the available data indicate the need to optimize patient-related factors that can impact TRM. We advocate for a shared decision-making approach, with a discussion of risks and benefits as well as the uncertainties with the patient. Patients with very high-risk disease or those at high risk of leukemic transformation should be considered for early transplantation. In contrast, it may be reasonable to closely monitor selected intermediate-2 risk patients who remain minimally symptomatic with a good performance status, with a plan for expeditious transplant at disease progression.
